Aditxt Seeks Shareholder Nod for Equity Issuances, Reverse Split, Name Change

TL;DR

**ADTX is scrambling to stay Nasdaq compliant and boost its stock price with a massive reverse split and rebranding, signaling deep trouble ahead.**

AI Summary

Aditxt, Inc. (ADTX) is convening a Special Meeting on January 30, 2026, to address several critical proposals aimed at ensuring Nasdaq compliance and strategic operational changes. Key proposals include seeking stockholder approval for the issuance of common stock underlying Series A-1 Convertible Preferred Stock issued in December 2023, Series C-1 Convertible Preferred Stock and warrants from May and August 2024, and warrants from July 2024, all to satisfy Nasdaq Marketplace Rule 5635(d). The company also proposes to increase the shares available under its 2021 Omnibus Equity Incentive Plan from 3 shares to 350,000 shares and to adopt a new 2025 Employee Stock Purchase Plan. Furthermore, Aditxt is seeking a non-binding advisory vote to change its name to 'bitXbio, Inc.' and to grant its board discretionary authority to effect a reverse stock split at a ratio between one-for-five (1:5) and one-for-two hundred fifty (1:250) within one year. These actions collectively aim to improve the company's financial flexibility, employee incentives, and potentially its stock price and market perception.

Why It Matters

This DEF 14A filing is crucial for Aditxt investors as it outlines significant corporate actions that could impact share dilution, employee incentives, and stock valuation. Approving the equity issuances is vital for Nasdaq compliance, preventing potential delisting. The proposed reverse stock split, ranging from 1:5 to 1:250, could drastically alter the per-share price, potentially attracting institutional investors but also signaling underlying financial distress. The name change to 'bitXbio, Inc.' suggests a strategic pivot or rebranding effort to customers and the broader market, potentially to align with new business ventures or technologies, while the increased equity incentive plan is key for employee retention and motivation in a competitive biotech landscape.

Risk Assessment

Risk Level: high — The filing indicates high risk due to multiple proposals for significant share issuances (Series A-1, Series C-1, July Warrants) which could lead to substantial dilution for existing shareholders. Furthermore, the proposed reverse stock split with a wide range of 1:5 to 1:250 suggests the company is facing severe stock price challenges, often a precursor to further declines or delisting, despite the intention to meet Nasdaq listing requirements.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the proposed equity issuances and the implications of a reverse stock split, which often fails to provide long-term value. Consider reducing exposure or holding off on new investments until the company demonstrates a clear path to sustainable growth and improved financial health beyond these reactive measures.

Key Numbers

• 350,000 shares — Proposed increase in shares for 2021 Omnibus Equity Incentive Plan (Increased from 3 shares, indicating a significant expansion of employee incentives.)
• 1:5 to 1:250 — Range for proposed reverse stock split ratio (Indicates a wide potential adjustment to share price, reflecting significant volatility or low stock price.)
• December 2023 — Issuance date of Series A-1 Convertible Preferred Stock (Relevant for Nasdaq compliance proposal.)
• May 2024 and August 2024 — Issuance dates of Series C-1 Convertible Preferred Stock and warrants (Relevant for Nasdaq compliance proposal.)
• July 2024 — Issuance date of common stock purchase warrants (Relevant for Nasdaq compliance proposal.)
• January 30, 2026 — Date of Special Meeting of Stockholders (When all proposals will be voted on.)
• December 5, 2025 — Record Date for voting eligibility (Determines which stockholders can vote at the Special Meeting.)
• 1,776,023 shares — Common stock outstanding on Record Date (Total shares eligible to vote at the Special Meeting.)
• 592,008 shares — Shares required for a quorum (One-third of outstanding shares needed to conduct business at the Special Meeting.)

Key Players & Entities

• Aditxt, Inc. (company) — Registrant and company undergoing significant corporate actions
• Nasdaq Marketplace Rule 5635(d) (regulator) — Rule requiring shareholder approval for certain equity issuances
• Amro Albanna (person) — Chief Executive Officer and Chairman of the Board of Directors
• Thomas J. Farley (person) — Chief Financial Officer
• Christopher J. Porcelli (person) — General Counsel
• Kingsdale Advisors (company) — Strategic Stockholder Advisor and Proxy Solicitation Agent
• VStock Transfer, LLC (company) — Company's transfer agent
• bitXbio, Inc. (company) — Proposed new name for Aditxt, Inc.
• U.S. Securities and Exchange Commission (regulator) — Regulatory body requiring proxy statements

FAQ

Risk Factors

• Nasdaq Compliance Failure [high — regulatory]: The company is seeking stockholder approval for several stock issuances to comply with Nasdaq Marketplace Rule 5635(d). Failure to obtain approval could result in delisting from the Nasdaq Stock Market, significantly impacting liquidity and investor confidence.
• Reverse Stock Split Necessity [high — operational]: The company is proposing a reverse stock split with a ratio between 1:5 and 1:250. This wide range suggests the current stock price is significantly below Nasdaq's minimum bid price requirement, indicating potential financial distress or a need to artificially inflate the share price.
• Dilution Risk from Equity Issuances [medium — financial]: The approval of multiple convertible preferred stock and warrant issuances, along with an increase in the equity incentive plan shares, will lead to significant dilution for existing common stockholders. The total number of shares to be issued is not fully quantified but is substantial enough to require shareholder approval under Nasdaq rules.
• Dependence on Stockholder Approval [high — operational]: The company's ability to maintain Nasdaq listing and implement strategic changes is contingent on the approval of multiple proposals at the Special Meeting on January 30, 2026. Any failure to secure the necessary votes could jeopardize the company's future.
• Employee Stock Purchase Plan Adoption [low — operational]: The adoption of the 2025 Employee Stock Purchase Plan (ESPP) aims to incentivize employees but also represents a potential future source of dilution and increased share count.

Industry Context

Aditxt operates in the biotechnology and diagnostics sector, a highly competitive and rapidly evolving industry. Companies in this space often rely on significant capital investment for research and development, and face stringent regulatory hurdles. Success is frequently tied to the ability to secure funding, achieve clinical milestones, and navigate complex intellectual property landscapes. The current market sentiment for many small-cap biotech firms can be volatile, influenced by trial results, regulatory approvals, and broader economic conditions.

Regulatory Implications

The primary regulatory concern for Aditxt is maintaining its listing on the Nasdaq Stock Market. The company is actively seeking shareholder approval for several stock issuances to comply with Nasdaq Marketplace Rule 5635(d). Failure to gain approval for these proposals could lead to delisting, which would severely impact the company's liquidity and investor base.

What Investors Should Do

1. Review all proposals carefully: Understand the implications of approving stock issuances for Nasdaq compliance, the increase in the equity incentive plan, the new ESPP, the name change, and the potential reverse stock split.
2. Vote your shares: Ensure your vote is cast by the deadline to help achieve a quorum and to express your support or opposition to the proposed actions. Your vote is crucial for the company's Nasdaq compliance and strategic direction.
3. Consider the dilution impact: Evaluate how the proposed stock issuances and equity plans might dilute your ownership percentage and the potential impact on share value.
4. Assess the reverse stock split rationale: Understand why the company is proposing such a wide range for a reverse stock split and its potential effect on the stock price and market perception.

Key Dates

• 2026-01-30: Special Meeting of Stockholders — This is the date when stockholders will vote on critical proposals, including Nasdaq compliance measures, equity plan amendments, name change, and a reverse stock split. The outcome will significantly impact the company's future.
• 2025-12-05: Record Date for voting eligibility — Determines which stockholders are eligible to vote at the Special Meeting. As of this date, there were 1,776,023 shares of common stock outstanding.
• 2023-12-01: Series A-1 Convertible Preferred Stock issuance — This issuance is one of the key events requiring stockholder approval for Nasdaq compliance under Rule 5635(d).
• 2024-05-01: Series C-1 Convertible Preferred Stock and warrants issuance — This issuance, along with others, requires stockholder approval to satisfy Nasdaq's equity issuance rules.
• 2024-08-01: Series C-1 Convertible Preferred Stock and warrants issuance — This issuance, along with others, requires stockholder approval to satisfy Nasdaq's equity issuance rules.
• 2024-07-01: Common stock purchase warrants issuance — This issuance requires stockholder approval for Nasdaq compliance under Rule 5635(d).

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC by a company to solicit shareholder votes for a specific meeting. (This document outlines the proposals Aditxt, Inc. is asking shareholders to vote on at their Special Meeting.)

Nasdaq Marketplace Rule 5635(d)

A Nasdaq rule requiring shareholder approval for certain issuances of securities that could result in a 20% or greater change in the outstanding common stock or voting power. (Aditxt is seeking approval for multiple stock and warrant issuances to comply with this rule and avoid potential delisting.)

Convertible Preferred Stock

A class of preferred stock that can be converted into a specified number of shares of common stock. (Several series of convertible preferred stock have been issued, and their underlying common stock issuances require shareholder approval.)

Common Stock Purchase Warrants

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's common stock at a specified price within a certain timeframe. (Warrants have been issued, and their underlying common stock issuances require shareholder approval for Nasdaq compliance.)

2021 Omnibus Equity Incentive Plan

A company plan that allows for the granting of stock options, restricted stock, and other equity awards to employees and directors. (Aditxt is proposing to significantly increase the number of shares available under this plan, from 3 to 350,000.)

Employee Stock Purchase Plan (ESPP)

A plan that allows employees to purchase company stock, often at a discount, through payroll deductions. (Aditxt is proposing to adopt a new ESPP, which could increase employee ownership and potential dilution.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into a smaller number of shares. (Aditxt is seeking discretionary authority to effect a reverse stock split, likely to increase its stock price and meet Nasdaq's minimum bid price requirement.)

Quorum

The minimum number of shareholders or directors required to be present at a meeting for business to be legally transacted. (A quorum of one-third of outstanding shares (592,008 shares) is needed for the Special Meeting to be valid.)

Year-Over-Year Comparison

This filing represents a significant shift from previous periods, focusing heavily on critical corporate actions required for Nasdaq compliance and future operational flexibility. Unlike prior filings that might have detailed ongoing operations or financial performance, this DEF 14A is dominated by proposals for shareholder approval. Key metrics such as revenue, net income, and margins are not detailed in this proxy statement, as its purpose is to solicit votes rather than provide a comprehensive financial update. The primary focus is on the proposals themselves and their necessity for the company's continued listing and strategic adjustments.

Filing Documents

• ea0269766-def14a_aditxt.htm (DEF 14A) — 1763KB
• image_001.jpg (GRAPHIC) — 3KB
• image_002.jpg (GRAPHIC) — 9KB
• image_003.jpg (GRAPHIC) — 3KB
• image_004.jpg (GRAPHIC) — 3KB
• image_005.jpg (GRAPHIC) — 3KB
• image_006.jpg (GRAPHIC) — 2KB
• image_007.jpg (GRAPHIC) — 3KB
• 0001213900-25-122329.txt ( ) — 1800KB

From the Filing

DEF 14A 1 ea0269766-def14a_aditxt.htm DEFINITIVE PROXY STATEMENT UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 Aditxt, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11 2569 Wyandotte Street, Suite 101 Mountain View, CA 94043 December 16, 2025 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held on January 30, 2026 Dear Stockholder: We are pleased to invite you to attend the special meeting of stockholders (the “Special Meeting”) of Aditxt, Inc. (the “Company”), which will be held on January 30 , 2026 at 12:00 PM ET. The Special Meeting will be held in a virtual-only meeting format at www.virtualshareholdermeeting.com/ADTX2026SM. In addition to voting by submitting your proxy prior to the Special Meeting, you also will be able to vote your shares electronically during the Special Meeting. Further details regarding the virtual meeting are included in the accompanying proxy statement. At the Special Meeting, the holders of our outstanding common stock will act on the following matters: 1. To approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying shares of Series A-1 Convertible Preferred Stock originally issued by the Company in December 2023 (the “Series A-1 Proposal”); 2. To approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying shares of Series C-1 Convertible Preferred Stock and common stock purchase warrants originally issued by the Company in May 2024 and August 2024 (the “Series C-1 Proposal”); 3. To approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying common stock purchase warrants originally issued by the Company in July 2024 (the “July Warrant Proposal”); 4. To approve the Company’s 2025 Employee Stock Purchase Plan (the “ESPP”) (the “ESPP Proposal”); 5. To approve an amendment to our 2021 Omnibus Equity Incentive Plan (the “2021 Plan”) to increase the number of shares of common stock issuable thereunder to 350,000 shares from 3 shares (the “Equity Incentive Proposal”); 6. To consider and cast a non-binding, advisory vote on the Company’s proposed amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to change the Company’s name from “Aditxt, Inc.” to “bitXbio, Inc.” (the “Name Change Proposal”); 7. To grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-five (1:5) to a maximum of a one-for-two hundred fifty (1:250) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders (the “Reverse Split Proposal”); 8. To authorize the adjournment of the Special Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting or adjournment or postponement thereof to approve any of the foregoing proposals (the “Adjournment Proposal”); and 9. To transact such other matters as may properly come before the Special Meeting and any adjournment or postponement thereof. Our board of directors has fixed December 5, 2025 as the record date (the “Record Date”) for the determination of stockholders entitled to notice of, and to vote at, the Special Meeting and at any adjournment or postponement of the meeting. IF YOU PLAN TO ATTEND: To be admitted to the Special Meeting at you must have your control number available and follow the instructions found on your proxy card or voting instruction form. You may vote during the Special Meeting by following the instructions available on the meeting website during the meeting. Please allow sufficient time before the Special Meeting to complete the on

View Full Filing

View this DEF 14A filing on SEC EDGAR